Key Takeaways Semaglutide produces clinically significant weight loss the STEP 1 trial demonstrated a mean 14.9% body weight reduction at 68 weeks with the 2.4 mg dose The dose escalation schedule is medically necessary, not optional rushing it leads to severe GI side effects that cause most treatment discontinuations Semaglutide is a long-term medication weight returns if treatment is stopped, as shown in the STEP 1 extension trial It carries real contraindications including a family history of medullary thyroid carcinoma, MEN2, pregnancy, and severe GI disease Drug interactions with oral medications are clinically relevant your full medication list must be reviewed by a pharmacist or physician before starting Maximum benefit requires combining semaglutide with a healthy diet and physical activity it reduces appetite, but it does not replace lifestyle modification References Wilding JPH, Batterham RL, Calanna S, et al

But low rates of adherence mean that these too, are not often sustainable for long term weight management (5)
Phase 2 data showed 24.2% weight loss at 48 weeks with no plateau, and Phase 3 TRIUMPH-4 data confirmed continued loss to 28.7% at 68 weeks
As a practitioner, I see this all the time
COA verified peptide bundle with syringes and supplies, shipped securely with consistent quality
How Brello Health works, what the semaglutide with B6 formulation actually contains and why B6 is included, how the pricing breaks down over time, what real users say on verified platforms, and how it compares to alternatives in the compounded GLP-1 market